Jack Kellie is currently a Group Director of Integrated Bioanalysis at AstraZeneca, where they apply their expertise in mass spectrometry and large molecule analysis. Previously, Jack served as a Post-Doctoral Scientist at Eli Lilly and Company, developing assays for protein quantitation related to Parkinson's disease. Jack’s academic background includes a Ph.D. in Chemistry from Northwestern University, during which they focused on intact protein analytical platforms and collaborated with industry leaders on proteomic workflows. They also contributed to research as an Undergraduate Researcher at Indiana University Bloomington and have held various roles at GSK and AstraZeneca.
This person is not in the org chart
This person is not in any teams
This person is not in any offices